SGShreya Sri Gopikonda

Shreya Sri Gopikonda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shreya Sri Gopikonda has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Outcomes of GLP-1 receptor agonist use following ischemic stroke: a propensity score-matched real-world analysis

    by Pranjal Rai, Girish Bathla, Niharika Praveen, Shreya Sri Gopikonda, Huanwen Alvin Chen, Hamza A. Salim, Ahmed Azzam, Muhammed Amir Essibayi, David J. Altschul, Adam A. Dmytriw, et al.

    Background Glucagon-like peptide-1 receptor agonists (GLP-1As) have been shown to be beneficial in primary stroke prevention for high-risk patients. However, their benefits following major ischemic events are unclear. Herein, we present real-world analysis assessing outcomes of GLP-1A following major ischemic event. Methods This retrospective cohort study utilized the TriNetX platform. Adults (≥ 18 years) with AIS treated with intravenous thrombolysis (IVT) were identified; exposure was any US FDA-approved GLP-1A initiated within 6 months of the index stroke. The comparator was IVT-treated patients without GLP-1A exposure. Outcomes assessed at 5 years included major adverse health-care events (MAHEs): number of emergency department (ED) visits and inpatient hospitalizations, and all-cause mortality. One-to-one propensity score matching balanced baseline characteristics. We estimated risk difference/risk ratio/odds ratio, 5-year Kaplan–Meier (KM) event probabilities with log-rank tests, and Cox hazard ratios (HRs) with 95% CIs; small cells (≤ 10) were masked per data-use agreement. Results Of 69,005 eligible patients, 549 received GLP-1A and 68,938 did not; after matching, 432 per group were analyzed. GLP-1A exposure was associated with lower all-cause mortality (7.4% vs 14.1%; HR 0.61, 95% CI 0.39–0.93), lower ED visits (37% vs 47%; HR 0.78, 95% CI 0.63–0.95), and lower inpatient hospitalizations (31.9% vs 45.4%; HR 0.69, 95% CI 0.55–0.85); KM log-rank p ≤ 0.05 for all. Median time to first MAHE was longer with GLP-1A (1293 vs 897 days for hospitalization and 886 vs 603 days for ED visits). Conclusions GLP-1A therapy after IVT is associated with favorable long-term safety and utilization signals and warrants confirmation in a prospective study with standardized initiation.


  • Unilateral Primary Angiitis of the Central Nervous System: A Rare and Under-Recognized Entity

    by Pranjal Rai, Neetu Soni, Shreya Sri Gopikonda, John C. Benson, Theodore J. Passe, Felix E. Diehn, Steven A. Messina, Victoria M. Silvera, Amit Agarwal, Girish Bathla

    Primary angiitis of the central nervous system (PACNS) is an uncommon inflammatory vasculitis restricted to the brain, spinal cord, and/or the leptomeninges. While typically bilateral, a rare subset presents with strictly unilateral involvement. This variant remains underrecognized and is often misdiagnosed as glioma, demyelination, or chronic encephalitis due to overlapping clinical and imaging features. Unilateral PACNS (U-PACNS) may manifest as tumor-like solitary or multifocal lesions, infarcts, or hemorrhages. Imaging, including vessel wall imaging (VWI), perfusion and spectroscopy may demonstrate underlying abnormalities but are often non-specific. Histopathologically, most cases show small-to medium-vessel lymphocytic vasculitis, in contrast to granulomatous inflammation which is more common in bilateral disease. Diagnosis is challenging, particularly in angiography-negative presentations, and often relies on excluding systemic, infectious, and neoplastic mimics. Recognition of U-PACNS is critical, as timely immunosuppressive therapy can avoid misdiagnosis, alter disease course and prevent irreversible deficits. The authors found 49 reported cases of U-PACNS in the English literature. Herein, we present a review of this rare and underrecognized entity, outlining key imaging features, and pertinent differentials that may help with a more accurate and timely non-invasive diagnosis. ABBREVIATIONS: U-PACNS= Unilateral Primary Angiitis of the Central Nervous System; CSF=Cerebrospinal Fluid; TLM= Tumor-like Mass; UR-PACNS=Unilateral Relapsing Primary Angiitis of the Central Nervous System.


  • Giant perivascular spaces causing obstructive hydrocephalus

    by Pranjal Rai, Shreya Sri Gopikonda, Dhairya A. Lakhani